Praxis Precision Medicines has raised $110 million to take its three clinical-phase central nervous system treatments forward. The pipeline is led by a GABAA positive allosteric modulator that is closing in on the start of a pivotal trial in depression.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,